No SE services | SE services | |||
---|---|---|---|---|
Referent (n=45) | Any (n=15) | Age <2 (n=10) | Age ≥2 (n=14) | |
Autoantibody features | ||||
APS | 4 (9) | 5 (33)* | 3 (30) | 5 (36)** |
aPLs | ||||
LA | 16 (36) | 11 (73) | 9 (90)** | 10 (71) |
aCL—IgG | 9 | 6 | 5 | 5 |
aCL—IgM | 0 | 0 | 0 | 0 |
anti-β2GPI—IgG | 0 | 0 | 0 | 0 |
anti-β2GPI—IgM | 1 | 0 | 0 | 0 |
Anti-Ro/SSA | 16 (36) | 3 (20) | 2 (20) | 2 (14) |
Anti-Ro among APS+ | 1 (2) | 1 (7) | 0 (0) | 1 (7) |
Anti-La/SSB | 8 (18) | 1 (7) | 0 (0) | 1 (7) |
Anti-La among APS+ | 2 (4) | 1 (7) | 0 (0) | 1 (7) |
Propensity Score† | 0.12 (0.19–0.15) | 0.16 (0.10–0.30)* | 0.16 (0.09–0.17) | 0.18 (0.12–0.30)** |
Data are presented as frequency (%) for categorical variables or median (IQR) for continuous variables.
*p<0.05;
**p≤0.01.
†Propensity score (for APS) uses non-fluorinated steroids, WHO class III and up for renal biopsy, and flare during pregnancy.